

# Parexel International Corporation

[View the current Parexel International Corporation Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/8083-Parexel+International+Corporation.html)

(<http://www.bioportfolio.com/biocorporate/8083-Parexel+International+Corporation.html>)

## Contact Details:

195 West Street

Waltham

MA

02154

United States of America

Tel: 781 487-9900

Fax: (781) 487-0525

Email: [kate.mccorrison@parexel.com](mailto:kate.mccorrison@parexel.com)

PAREXEL International Corporation is a leading contract research and medical marketing services organization providing a broad spectrum of services from first-in-human clinical studies through product launch to the pharmaceutical, biotechnology, and medical device industries around the world. The Company's primary objective is to help clients quickly obtain the necessary regulatory approvals of their products and, ultimately, optimize the market penetration of those products. Over the past fifteen years, PAREXEL has developed significant expertise in disciplines supporting this strategy. The Company's service offerings include: clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, performance improvement, industry training and publishing, and other drug development consulting services. The Company believes that its integrated services, therapeutic area depth, and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths.

## Recent Publications by Parexel International Corporation:



- [Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke.](#)  
*BACKGROUND AND PURPOSE: Numerous preclinical findings and a clinical pilot...* 17th October, 2009  
From the Division of Clinical Neuroscience, Max Planck Institute of- Stroke. 2009 Oct 15. ([DOI Direct Link](#))
- [Recent trends in lung cancer and its association with COPD: an analysis using the UK GP Research Database.](#)  
*BACKGROUND: The association between lung cancer and COPD has not been...* 17th September, 2009  
PAREXEL International, PACE, London, UK.- Prim Care Respir J. 2009 Sep 15. pii: pcrj-2009-02-0021.

doi: ([DOI Direct Link](#))

- [How real is intention-to-treat \(ITT\) analysis in non-interventional post authorization safety studies? We can do better.](#)  
*Although cohort studies which are based on intention-to-treat (ITT)...*31st July, 2009  
Peri-Approval, Clinical Research Services, PAREXEL International,- Curr Drug Saf. 2009 May;4(2):137-42.
- [Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.](#)  
*Maribavir, an oral antiviral drug with activity against cytomegalovirus,...*14th August, 2008  
PAREXEL International, Baltimore, Maryland, USA.- Antimicrob Agents Chemother. 2008 May;52(5):1794-8. Epub 2008 Mar 3. ([DOI Direct Link](#))
- [Is it necessary to use a noseclip in the performance of spirometry using a wedge bellows device?](#)  
*There is no current consensus among published guidelines on whether...*12th May, 2007  
PAREXEL International, Northwick Park Hospital, Harrow, UK.- Chron Respir Dis. 2007;4(1):53-7.
- [Defining the competencies of those conducting pharmacovigilance.](#)  
*PURPOSE: The absence of agreed competencies in pharmacovigilance and...*9th December, 2006  
Medical Services, PAREXEL International Ltd., Uxbridge, Middlesex, UK.- Pharmacoepidemiol Drug Saf. 2006 Mar;15(3):193-8. ([DOI Direct Link](#))
- [Safety and tolerability of high-dose formoterol \(via Aerolizer\) and salbutamol in patients with chronic obstructive pulmonary disease.](#)  
*To evaluate the safety and tolerability of high-dose formoterol and...*31st October, 2006  
PAREXEL International GmbH, Klinikum Westend, Haus 18, Spandauer Damm 130,- Respir Med. 2006 Apr;100(4):666-72. Epub 2005 Nov 21. ([DOI Direct Link](#))
- [A tribute to Sidney Farber-- the father of modern chemotherapy.](#)  
*Sidney Farber, world-renowned paediatric pathologist, made major...*17th August, 2006  
PAREXEL International,- Br J Haematol. 2006 Jul;134(1):20-6. ([DOI Direct Link](#))
- [Drug interactions during therapy with three major groups of antimicrobial agents.](#)  
*This review focuses on drug-drug interactions with three major groups of...*28th June, 2006  
PAREXEL International GmbH, Institute of Clinical Pharmacology, Clinical- Expert Opin Pharmacother. 2006 Apr;7(6):639-51. ([DOI Direct Link](#))
- [Safety and tolerability of high-dose formoterol \(Aerolizer\) and salbutamol \(pMDI\) in patients with mild/moderate, persistent asthma.](#)  
*This double-blind, double-dummy, crossover study evaluated the...*25th May, 2005  
PAREXEL International GmbH, Institute of Clinical Pharmacology, Berlin,- Pulm Pharmacol Ther. 2005;18(3):229-34. ([DOI Direct Link](#))
- [Managing the interface with marketing to improve delivery of pharmacovigilance within the pharmaceutical industry.](#)  
*The pharmaceutical industry is under pressure to improve the scientific...*15th September, 2004  
PAREXEL International,- Drug Saf. 2004;27(8):609-17.
- [A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point.](#)  
*OBJECTIVE: To use a composite efficacy/tolerability end point to compare...*20th August, 2004  
PAREXEL International, The Quays, 101-105 Oxford Rd., Uxbridge, Middlesex,- J Manag Care Pharm. 2004 May-Jun;10(3):259-65.
- [Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine.](#)  
*BACKGROUND: Migraine is a common disorder that costs US employers billions...*26th March, 2004  
PAREXEL International, Uxbridge, Middlesex, United Kingdom.- Clin Ther. 2003 Nov;25(11):2903-19.
- [Compliance with oral HRT in postmenopausal women in clinical trials--meta analysis.](#)  
*OBJECTIVE: To assess compliance with oral hormone replacement therapy...*12th February, 2004  
Rose Tree Corporation Center, PAREXEL International, 1400 N Providence- Maturitas. 2003 Sep 25;46(1):33-44.

## Press Releases on Parexel International Corporation:

<a href="#">FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review</a>	24th November, 2009	Eisai Inc.	<p>WOODCLIFF LAKE, N.J. and NEW YORK, Nov. 24 /PRNewswire/ -- Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's New Drug BETHESDA, Md., Nov. 24 /PRNewswire-Asia/ -- Chindex International, Inc. ("Chindex") (Nasdaq: CHDX), a leading independent American provider of Western healthcare products and services in</p>
<a href="#">Chindex International to Present at Piper Jaffray Health Care Conference</a>	24th November, 2009	Chindex International, Inc.	<p>PLYMOUTH MEETING, Pa., Nov. 24 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone Corporation (Nasdaq: BJGP) ("BMP Sunstone" or the "Company") today announced that the Company will</p>
<a href="#">BMP Sunstone to Present at Piper Jaffray Health Care Conference</a>	24th November, 2009	BMP Sunstone Corporation	<p>NOVATO, Calif., Nov. 24 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company</p>
<a href="#">BioMarin to Present at the NASDAQ OMX 23rd Investor Program</a>	24th November, 2009	BioMarin Pharmaceutical Inc.	<p>ST. LOUIS, Nov. 24 /PRNewswire-FirstCall/ -- Centene Corporation (NYSE: CNC) today announced that the Mississippi Division of Medicaid has selected Centene as one of two Coordinated Care Organizations</p>
<a href="#">Centene Corporation Receives Notification of Intent to Contract From the State of Mississippi</a>	24th November, 2009	Centene Corporation	

## BioNews Results for Parexel International Corporation



- [PAREXEL Experts to Discuss Impact of Pharmacovigilance Trends on Biosimilars and Generics at World Generic Med](#)  
*PR Newswire: Nov 23 2009 12:43AM Matching: parexel international*
- [PAREXEL Experts to Discuss Impact of Pharmacovigilance Trends on Biosimilars and Generics at World Generic Med](#)  
*Pharma Live: Nov 19 2009 2:36PM Matching: parexel international*
- [New Jersey Leaders in Medicine, Biotechnology and Discovery Join Richard Gephardt for 'Best and](#)

## [Brightest Foru](#)

*RBC Dain Rauscher: Nov 19 2009 5:46AM Matching: parexel international*

- [New Jersey Leaders in Medicine, Biotechnology and Discovery Join Richard Gephardt for 'Best and Brightest Foru](#)

*NewsBlaze: Nov 19 2009 12:54AM Matching: parexel international*

- [PAREXEL Experts to Discuss Impact of Pharmacovigilance Trends on Biosimilars and Generics at World Generic Med](#)

*Pharmacy Choice: Nov 18 2009 8:49PM Matching: parexel international*

- [Insights into evolving pharmacovigilance trends and their impact on biosimilars and generic products](#)

*News-Medical.Net: Nov 18 2009 7:39PM Matching: parexel international*

- [PAREXEL Experts to Discuss Impact of Pharmacovigilance Trends on Biosimilars and Generics at World Generic Medicines Congress Americas](#)

*Individual.com: Nov 18 2009 9:05PM Matching: parexel international*

- [New Jersey Leaders in Medicine, Biotechnology and Discovery Join Richard Gephardt for 'Best and Brightest Foru](#)

*Biz Journals: Nov 18 2009 10:41PM Matching: parexel international*

- [New Jersey Leaders in Medicine, Biotechnology and Discovery Join Richard Gephardt for 'Best and Brightest Foru](#)

*Reuters: Nov 18 2009 10:21PM Matching: parexel international*

- [New Jersey Leaders in Medicine, Biotechnology and Discovery Join Richard Gephardt for 'Best and Brightest Foru](#)

*Houston Chronicle: Nov 18 2009 10:19PM Matching: parexel international*

- [Nuclear Imaging Capabilities Expanded for Cardiology Trials](#)

*Medicexchange.com: Nov 18 2009 10:13PM Matching: parexel international*

- [Parexel International Allies with Mortara Instrument](#)

*Applied Clinical Trials: Nov 17 2009 3:31PM Matching: parexel international*

- [Perceptive Informatics Expands Nuclear Imaging Capabilities for Cardiology Trials](#)

*Yahoo! Canada: Nov 17 2009 2:20PM Matching: parexel international*

- [Perceptive Informatics announces the expansion of its medical imaging capabilities for cardiology clinical trials](#)

*News-Medical.Net: Nov 17 2009 12:37PM Matching: parexel international*

- [PAREXEL Experts to Discuss Global Capabilities to Meet Urgent Demand For Cardiovascular Treatments at AHA Scie](#)

*Freshnews.com: Nov 16 2009 12:02PM Matching: parexel international*

## **Parexel International Corporation Clinical Trials:**



- [Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia](#)

## **BioCorporate Profiles - upgrade to a full profile**

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services.

BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

